Faculty profile

Guila Delouya

Back to faculty

ProfessorDépartement de radiologie, radio-oncologie et médecine nucléaireUniversité de Montréal

Guila Delouya

Professor

Département de radiologie, radio-oncologie et médecine nucléaire

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
15 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

594

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Google Scholar ResearchGate iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Latest papers

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer
JAMA · 2026
Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation.
JNCI cancer spectrum · 2026
The importance of the season of biopsy on the Gleason score on biopsy: does exposure to sunshine have an influence?
Asian journal of andrology · 2026 · first author

All 59 publications

Latest funding

AI tools for the integration of MRI in planning and motion management phases in cone-beam CT workflows for upper abdominal and lung cancer treatments
NSERC · 2023 · Co-investigator
$187,000

All 1 grants and awards

59 publications.

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Rodney J. Ellis, Stephanie L. Pugh, James B. Yu, Felix Y. Feng, Andre A. Konski, Robert L. Grubb, Robert E. Wallace, David J. Gladstone, Cynthia Ménard, Joseph A. Miccio, Arthur J. Frazier, J. Daniel Pennington, Jeff M. Michalski, Daniel E. Spratt, Alvaro Martinez, Scott C. Morgan, Alina Mihai, Abhishek Ashok Solanki, Asim Amjad, Michael W. Straza, Guila Delouya, Thomas Schroeder, David T. Marshall, Nirav Kapadia, Akshar N. Patel, Terrence P. Cescon, Ali El-Gayed, Harold A. Yoon, Rebecca Paulus, Howard M. Sandler, et al. (31 authors)

JAMA20262 citationsOpen Access

DOI: 10.1001/jama.2026.12627 PMID: 42593775

Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation.

Benisti S, Saad F, Delouya G, Taussky D

JNCI cancer spectrum2026

DOI: 10.1093/jncics/pkag075 PMID: 42439540

The importance of the season of biopsy on the Gleason score on biopsy: does exposure to sunshine have an influence?

Delouya G, Taussky D

Asian journal of andrology2026First author

DOI: 10.4103/aja202536 PMID: 40625104

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD

JAMA Oncology2025116 citationsOpen Access

DOI: 10.1001/jamaoncol.2024.5403

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Niazi T, Saad F, Tisseverasinghe S, Koul R, Thibault I, Chung PWM, Wakil G, Lock M, Delouya G, Bahoric B

The Lancet Oncology202529 citations

DOI: 10.1016/s1470-2045(25)00351-1

Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy.

Margolese N, Dahan J, Olivié DAR, Billiard JS, Delouya G, Taussky D

The British journal of radiology2025

DOI: 10.1093/bjr/tqaf122 PMID: 40455006

Multicentric evaluation of recurrence's management after brachytherapy for localized prostate cancer.

Benchimol Y, Taussky D, Thiounn N, Bouche G, Ramiandrisoa F, Delouya G, Meynard C, Giraud P, Bibault JE, Kreps S, Timsit MO, Méjean A, Saad F, Larré S, Taha F, Dariane C

The French journal of urology2025

DOI: 10.1016/j.fjurol.2025.102910 PMID: 40412482

Addressing controversial areas in the management of advanced prostate cancer in Canada : Areas of consensus and controversy from the third Canadian consensus forum

Saad F, Hotte SJ, Noonan K, Malone S, Morash C, Niazi T, Rendon RA, Shayegan B, Basappa NS, Cagiannos I

Journal of the Canadian Urological Association2024Open Access

DOI: 10.5489/cuaj.8537 PMID: W4390106584

Tracing the Evolution of Prostate Brachytherapy in the 20th Century.

Schaulin MS, Delouya G, Zwahlen D, Taussky D

Oncology2024

DOI: 10.1159/000534017 PMID: 37806307

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Lukka HR, Deshmukh S, Bruner DW, Bahary J-P, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS

International Journal of Radiation Oncology Biology Physics202313 citationsOpen Access

DOI: 10.1016/j.ijrobp.2022.12.022

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Guila Delouya

Research

Latest papers

Latest funding

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation.

The importance of the season of biopsy on the Gleason score on biopsy: does exposure to sunshine have an influence?

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial

Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy.

Multicentric evaluation of recurrence's management after brachytherapy for localized prostate cancer.

Addressing controversial areas in the management of advanced prostate cancer in Canada : Areas of consensus and controversy from the third Canadian consensus forum

Tracing the Evolution of Prostate Brachytherapy in the 20th Century.

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

AI tools for the integration of MRI in planning and motion management phases in cone-beam CT workflows for upper abdominal and lung cancer treatments

Frequent collaborators

Jean-Paul Bahary

Maroie Barkati

Fred Saad

Jean-François Carrier

Houda Bahig

David Roberge

Krista Noonan

Michael Ong

Bobby Shayegan

Alan So

Antonio Finelli

Michael Lock

Kim Chi

Alexandra Rink

Ricardo Rendon

Alina Lalani

Peter Chung

Himu Lukka

Normand Blais

Mikhael Laskine

Denis Soulières

Ilias Cagiannos

Alejandro Berlin

Édith Filion

Louise Lambert

Asim Amjad

André-Guy Martin